Dendreon
Developer and manufacturer focused on cellular immunotherapies and cell therapy manufacturing. The organization supports research and development, clinical and commercial manufacture, logistics, and strategic partnerships to enable patient-specific and complex cell therapies.
Industries
Nr. of Employees
Very Large (1000+)
Patents
Gene expression markers for predicting overall survival in subjects treated with sipuleucel-T
US-11970743-B2
View DetailsHumoral immune response against tumor antigens after treatment with a cancer antigen specific active immunotherapy and its association with improved clinical outcome
US-10261091-B2
View DetailsMethods for inducing a natural killer (NK) cell-mediated immune response and for increasing NK cell activity
US-8153120-B2
View Details
Gene expression markers for predicting overall survival in subjects treated with sipuleucel-T
US-11970743-B2
View DetailsHumoral immune response against tumor antigens after treatment with a cancer antigen specific active immunotherapy and its association with improved clinical outcome
US-10261091-B2
View DetailsMethods for inducing a natural killer (NK) cell-mediated immune response and for increasing NK cell activity
US-8153120-B2
View DetailsProducts
FDA-cleared cellular immunotherapy for prostate cancer (commercialized)
A commercially distributed cellular immunotherapy indicated for prostate cancer; noted as the first FDA-approved cellular immunotherapy and received by nearly 40,000 patients.
FDA-cleared cellular immunotherapy for prostate cancer (commercialized)
A commercially distributed cellular immunotherapy indicated for prostate cancer; noted as the first FDA-approved cellular immunotherapy and received by nearly 40,000 patients.
Services
Manufacturing services for clinical- and commercial-stage cell therapies, including production workflows, facilities, and distribution support.
Support for clinical research, outcomes tracking, and real-world evidence generation to inform clinical and commercial use of cell therapies.
Operational and logistical services to manage transport, handling, and delivery of cell therapy products, including contingency planning for disruptions.
Manufacturing services for clinical- and commercial-stage cell therapies, including production workflows, facilities, and distribution support.
Support for clinical research, outcomes tracking, and real-world evidence generation to inform clinical and commercial use of cell therapies.
Operational and logistical services to manage transport, handling, and delivery of cell therapy products, including contingency planning for disruptions.
Expertise Areas
- Cell therapy manufacturing
- Cellular immunotherapy development
- Clinical trial operations for cell therapies
- Regulatory compliance for biologics and cell therapies
Key Technologies
- Cellular immunotherapy
- Cell therapy manufacturing processes
- Clinical operations for cell therapy trials
- Cold-chain and biologics logistics
News & Updates
Report of a large real-world study indicating nearly four years median survival in a cohort of men with advanced prostate cancer treated with the company's cellular immunotherapy.
News items describing public-awareness and marketing campaigns focused on prostate cancer disparities and awareness, including partnerships with public figures.
Discussion of how the supply chain for immunotherapies is impacted by events such as the COVID-19 pandemic and hurricanes, and measures for maintaining therapy delivery.
Brought the first FDA-approved cellular immunotherapy to market and treated nearly 40,000 patients according to the company website.
Report of a large real-world study indicating nearly four years median survival in a cohort of men with advanced prostate cancer treated with the company's cellular immunotherapy.
News items describing public-awareness and marketing campaigns focused on prostate cancer disparities and awareness, including partnerships with public figures.
Discussion of how the supply chain for immunotherapies is impacted by events such as the COVID-19 pandemic and hurricanes, and measures for maintaining therapy delivery.
Brought the first FDA-approved cellular immunotherapy to market and treated nearly 40,000 patients according to the company website.